期刊
SURGICAL LAPAROSCOPY ENDOSCOPY & PERCUTANEOUS TECHNIQUES
卷 20, 期 6, 页码 E230-E232出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/SLE.0b013e318200a115
关键词
metastatic colorectal cancer; bevacizumab (Avastin); colonic perforation; self-expandable metallic stent; digestive stenting; covered stent
类别
Angiogenesis inhibitors have markedly improved, in combination with chemotherapy, the outcome of patients with metastatic solid tumors. Bevacizumab, the brand name of which is Avastin, is the first monoclonal antibody IgG1 used against the vascular endothelial growth factor involved in tumor proliferation. Gastrointestinal perforation is a well-known adverse event of bevacizumab therapy. Its surgical management is still controversial because of the high mortality rate of surgery. Here, we report a 48-year-old man with a history of metastatic renal cancer, who developed colonic perforation secondary to bevacizumab. This patient was treated successfully with endoscopic stenting.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据